Liquid Biopsy can be used to track evolution of resistance

As of January 23, 2018 and March 29, 2018:

Plasma genotyping by Next Generation Sequencing (Liquid Biopsy) can be used to track evolution of resistance to various ALK inhibitors.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785105/

https://www.ncbi.nlm.nih.gov/pubmed/29599410

This entry was posted in Lung cancer, Research. Bookmark the permalink.

Leave a Reply